Cargando…

Does anti-VEGF bevacizumab improve survival in experimental sepsis?

Detalles Bibliográficos
Autores principales:	Besnier, Emmanuel, Brakenhielm, Ebba, Richard, Vincent, Tamion, Fabienne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497351/ https://www.ncbi.nlm.nih.gov/pubmed/28676101 http://dx.doi.org/10.1186/s13054-017-1734-x

Ejemplares similares

Hypertonic sodium lactate improves microcirculation, cardiac function, and inflammation in a rat model of sepsis
por: Besnier, Emmanuel, et al.
Publicado: (2020)

Therapeutic vascular growth in the heart
por: Brakenhielm, Ebba, et al.
Publicado: (2019)

Ventriculo-arterial (un)coupling in septic shock: Impact of current and upcoming hemodynamic drugs
por: Demailly, Zoé, et al.
Publicado: (2023)

Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab
por: Krizova, Deli, et al.
Publicado: (2014)

The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)
por: He, Kuifeng, et al.
Publicado: (2012)

A Weak Response to Endoplasmic Reticulum Stress Is Associated With Postoperative Organ Failure in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass
por: Clavier, Thomas, et al.
Publicado: (2021)

Anti-Xa activity and hemorrhagic events under extracorporeal membrane oxygenation (ECMO): a multicenter cohort study
por: Descamps, Richard, et al.
Publicado: (2021)

Alpha-2 adrenoceptor agonists and sepsis: improved survival?
por: Quintin, Luc
Publicado: (2010)

Gene Expression of Protein Tyrosine Phosphatase 1B and Endoplasmic Reticulum Stress During Septic Shock
por: Clavier, Thomas, et al.
Publicado: (2019)

Sodium lactate improves renal microvascular thrombosis compared to sodium bicarbonate and 0.9% NaCl in a porcine model of endotoxic shock: an experimental randomized open label controlled study
por: Duburcq, Thibault, et al.
Publicado: (2018)

Efficiency and safety of subconjunctival injection of anti-VEGF agent – bevacizumab – in treating dry eye
por: Jiang, Xiaodan, et al.
Publicado: (2015)

Soluble RAGE as a Prognostic Marker of Worsening in Patients Admitted to the ICU for COVID-19 Pneumonia: A Prospective Cohort Study
por: Besnier, Emmanuel, et al.
Publicado: (2022)

Pharmacologic inhibition of cholinesterase improves survival in experimental sepsis
por: Hofer, S, et al.
Publicado: (2007)

Comparison of Systemic Adverse Events Associated with Intravitreal Anti-VEGF Injection: Ranibizumab versus Bevacizumab
por: Hwang, Duck Jin, et al.
Publicado: (2012)

Routine and Advanced Laboratory Tests for Hemostasis Disorders in COVID-19 Patients: A Prospective Cohort Study
por: Billoir, Paul, et al.
Publicado: (2022)

Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes
por: MacDonald, Douglas A., et al.
Publicado: (2016)

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
por: Derangère, Valentin, et al.
Publicado: (2016)

Synthetic microparticles conjugated with VEGF(165) improve the survival of endothelial progenitor cells via microRNA-17 inhibition
por: Aday, Sezin, et al.
Publicado: (2017)

VEGF(165)b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy
por: Varey, A H R, et al.
Publicado: (2008)

Developing a Noninvasive Procedure Using Labeled Monoclonal Antibody Anti-VEGF (Bevacizumab) for Detection of Endometriosis
por: Machado, Daniel Escorsim, et al.
Publicado: (2015)

Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab
por: Schargus, Marc, et al.
Publicado: (2021)

Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells
por: Rusovici, Raluca, et al.
Publicado: (2011)

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
por: Papadopoulos, Nicholas, et al.
Publicado: (2012)

The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance
por: Alidzanovic, Lejla, et al.
Publicado: (2016)

Urinary albumin excretion is elevated in sepsis, but does not correlate with circulating VEGF-A levels
por: Basu, S, et al.
Publicado: (2010)

Additional bad news from regulatory T cells in sepsis
por: Monneret, Guillaume, et al.
Publicado: (2010)

The effect of intravitreal bevacizumab and ranibizumab on macular edema of the contralateral eye: A comparative study of two anti-VEGFs
por: Bakbak, Berker, et al.
Publicado: (2016)

Potential of an anti-bevacizumab idiotype scFv DNA-based immunization to elicit VEGF-binding antibody response
por: Silva, Tábata Almeida, et al.
Publicado: (2022)

Bevacizumab-Induced Geographic Tongue
por: Martinez-Garcia, Marta, et al.
Publicado: (2021)

Intravitreal bevacizumab
por: Khamar, Bakulesh M
Publicado: (2018)

Bevacizumab therapy normalizes the pathological intraocular environment beyond neutralizing VEGF
por: Sharma, Rajesh K., et al.
Publicado: (2010)

Morphological Changes of Cortical and Hippocampal Neurons after Treatment with VEGF and Bevacizumab
por: Latzer, Pauline, et al.
Publicado: (2016)

Blocking VEGF by Bevacizumab Compromises Electrophysiological and Morphological Properties of Hippocampal Neurons
por: Latzer, Pauline, et al.
Publicado: (2019)

Bevacizumab in Wet AMD treatment: A tribute to the thirteen years of experience from the beginning of the anti-VEGF era in Romania
por: Stanca, Horia T., et al.
Publicado: (2019)

Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab
por: Muñoz-Villegas, Patricia, et al.
Publicado: (2021)

Anti-VEGF and anti-EGFR agents open up new horizons changing the landscape for their associations
por: Milano, Gerard
Publicado: (2016)

Screening and Improvement of an Anti-VEGF DNA Aptamer
por: Nonaka, Yoshihiko, et al.
Publicado: (2010)

An experimental study of VEGF induced changes in vasoactivity in pig retinal arterioles and the influence of an anti-VEGF agent
por: Su, Er-Ning, et al.
Publicado: (2012)

Surviving sepsis bundle compliance: getting the time of the day it deserves
por: Borikar, Madhura, et al.
Publicado: (2013)

Endophthalmitis Outbreak Associated with Repackaged Bevacizumab
por: Edison, Laura S., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8dvrip2amul7aigvbb614rh74u